

## **Cryoport to Report Third Quarter 2022 Financial Results on November 3, 2022**

**NASHVILLE, Tennessee, October 27, 2022** - [Cryoport, Inc.](#) (Nasdaq: CYRX) (“Cryoport” or the “Company”), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced that the Company will report financial results for the three months period ended September 30, 2022 (third quarter 2022) on Thursday, November 3, 2022 after U.S. markets close.

In addition to the earnings release, a document titled “Cryoport Third Quarter 2022 in Review”, providing a review of Cryoport’s recent financial and operational performance and a general business update, will be issued at 4:05 pm ET on Thursday, November 3, 2022. The document is designed to be read in advance of the questions and answers conference call and will be accessible at <http://ir.cryoport.com/events-and-presentations>.

Cryoport management will host a conference call the same day at 5:00 pm ET. The conference call will be in the format of a questions and answers session and will address questions members of the investment community have regarding the Company’s reported results. A slide deck will accompany the call.

### **Conference Call Information**

Date: Thursday, November 3, 2022  
Time: 5:00 p.m. ET  
Dial-in numbers: 1-888-254-3590 (U.S.), 1-720-543-0214 (International)  
Confirmation code: Request the “Cryoport Call”  
Live webcast: ‘Investor Relations’ section at [www.cryoport.com](http://www.cryoport.com) or [click here](#).

Please allow 10 minutes prior to the call to visit this site to download and install any necessary audio software.

The questions and answers call will be recorded and available approximately three hours after completion of the live event in the Investor Relations section of the Company's website at [www.cryoport.com](http://www.cryoport.com) for a limited time. To access the replay of the questions and answers [click here](#). A dial-in replay of the call will also be available to those interested, until November 10, 2022.

To access the replay, dial 1-844-512-2921 (United States) or 1-412-317-6671 (International) and enter replay pin number: 6820976

**About Cryoport, Inc**

Cryoport, Inc. (Nasdaq: CYRX), headquartered in Nashville, TN, is a global leader in temperature-controlled supply chain solutions for the life sciences industry supporting life-saving cell and gene therapies across the clinical and commercial spectrum. With 38 strategic locations covering the Americas, EMEA (Europe, the Middle East and Africa) and APAC (Asia Pacific), Cryoport's global platform provides mission-critical solutions, services, and products to Biopharma, Animal Health, and Reproductive Medicine customers worldwide. In addition to its standard setting supply chain solutions, Cryoport is the world's largest manufacturer of cryogenic systems and one of the largest life science focused specialty couriers.

For more information, visit [www.cryoport.com](http://www.cryoport.com) or follow @cryoport on Twitter at [www.twitter.com/cryoport](https://www.twitter.com/cryoport) for live updates.

***Forward-Looking Statements***

Statements in this press release which are not purely historical, including statements regarding the Company's intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, those related to the Company's industry, business, long-term growth prospects, plans, strategy, acquisitions, future financial results and financial condition, such as the Company's outlook and guidance for full year 2022 revenue and the related factors expected to drive revenue, projected trends in the markets in which the Company operates, the Company's intention to expand overall manufacturing capacities, the Company's plan for a new Global Supply Chain Center in Paris, the Company's repurchases of shares of its common stock, and regulatory approvals with respect to the products of the Company's clients. It is important to note that the Company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effect of changing economic conditions, including as a result of the COVID-19 pandemic and its variants, supply chain constraints, inflationary pressures and the effects of foreign currency fluctuations, trends in the products markets, variations in the Company's cash flow, market acceptance risks, and technical development risks. The Company's business could be affected by a number of other factors, including the risk factors discussed in the Company's Securities and Exchange Commission ("SEC") reports including, but not limited to, the Company's Annual Report on Form 10-K for the year ended December 31, 2021, its Quarterly Reports on Form 10-Q filed with the SEC during 2022, as well as in its subsequent filings with the SEC. The forward-looking statements contained in this press release speak only as of the date hereof and the Company cautions investors not to place undue reliance on these forward-looking statements. Except as required by law, the Company disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.



SCIENCE. LOGISTICS. CERTAINTY.

**Cryoport Investor Contacts:**

Todd Fromer

KCSA Strategic Communication

tfromer@kcsa.com

P: 1-212-896-1203